Precision oncology coverage: Malaysia’s Malaysian Re and China Re Life signed a reinsurance treaty to build a dedicated framework for Cancer Precision Medicine, including CAR-T, targeted therapies and precision immunotherapy, with an overseas benefit for treatment at designated oncology centers in China—aimed at closing gaps where many Malaysian patients are diagnosed late. Medical device recall: Sri Lanka’s Medical Supplies Division ordered immediate withdrawal of specific batches of colostomy appliances and angiographic catheters supplied to government hospitals after reports of defects that could affect patient safety, including poor adhesion and skin irritation risk. Clinical trial milestone: Innovent Biologics dosed the first patient in a Chinese pivotal Phase 3 trial of IBI3003, a trispecific antibody for relapsed/refractory multiple myeloma, comparing it with investigator-chosen regimens. Health-tech & policy: WHO and UNAIDS warned HIV progress is “real but fragile” as funding cuts threaten prevention, testing and community-led services, with Asia-Pacific facing fast-rising epidemics in several countries. China health innovation: Boruikang’s STAR Market IPO application was accepted, positioning it as China’s first publicly traded brain-computer interface firm after its invasive BCI device gained Class III approval.